Volume | 39,727 |
|
|||||
News | - | ||||||
Day High | 1.71 | Low High |
|||||
Day Low | 1.68 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
ARCA Biopharma Inc | ABIO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.70 | 1.68 | 1.71 | 1.72 | 1.69 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
279 | 39,727 | $ 1.68 | $ 66,919 | - | 1.56 - 2.16 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:29:51 | 2 | $ 1.74 | USD |
ARCA Biopharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
24.8M | 14.50M | - | 0 | -5.34M | -0.37 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
ARCA Biopharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ABIO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.61 | 1.73 | 1.60 | 1.68 | 33,805 | 0.11 | 6.83% |
1 Month | 1.67 | 1.75 | 1.57 | 1.66 | 24,850 | 0.05 | 2.99% |
3 Months | 1.73 | 1.79 | 1.56 | 1.65 | 28,652 | -0.01 | -0.58% |
6 Months | 2.02 | 2.06 | 1.56 | 1.77 | 24,376 | -0.30 | -14.85% |
1 Year | 2.14 | 2.16 | 1.56 | 1.91 | 24,426 | -0.42 | -19.63% |
3 Years | 4.09 | 4.34 | 1.56 | 2.80 | 125,772 | -2.37 | -57.95% |
5 Years | 0.41 | 22.00 | 0.29 | 8.03 | 334,739 | 1.31 | 319.51% |
ARCA Biopharma Description
ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. |